Ngomhla wama-31 kuJulayi, i-AstraZeneca kunye ne-Merck & Co. babhengeze ngokudibeneyo ukuba i-Lynparza yabo ye-PARP inhibitor, kunye ne-Abiraterone kunye ne-prednisolone, ivunyiwe eTshayina kunyango lwezigulane zabantu abadala abanomhlaza we-prostate onganyangekiyo yi-metastatic castration (mCRPC) abane-germline okanye i-somatic BRCA mutations (gBRCAm okanye sBRCAm).
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
I-imeyile：myimmnet@163.com
I-Lynparza (olaparib) sisithinteli se-PARP sokuqala kudidi kwaye sisonyango lokuqala olujoliswe kulo ukuthintela impendulo yomonakalo we-DNA (DDR) kwiiseli/iithumba ezigcina ukungabikho kwe-HRR, njengokuguqulwa kwe-BRCA1 kunye/okanye i-BRCA2. Ukuthintelwa kwe-PARP nge-Lynparza kukhokelela ekubambeni i-PARP ebotshelelwe kwi-DNA single-strand breaks, ukumiswa kweefolokhwe zokuphindaphinda, ukuwohloka kwazo kunye nokuveliswa kwe-DNA double-strand breaks kunye nokufa kweeseli zomhlaza.
Olu vunywa lwalusekelwe ikakhulu kwiziphumo zohlalutyo lwamaqela amancinci ezivela kumaqela ehlabathi kunye namaTshayina ovavanyo lwe-PROpel Phase III. I-PROpel luvavanyo lweklinikhi lweSigaba III olucwangcisiweyo, olungaboni kabini, oluneendawo ezininzi oluvavanya ukusebenza kakuhle, ukhuseleko, kunye nokunyamezeleka kweLynparza xa idibene ne-Abiraterone kunye ne-prednisolone xa kuthelekiswa ne-placebo kunye ne-Abiraterone kunye ne-prednisolone kwizigulane ezingamadoda ezine-mCRPC ezingakhange zifumane i-chemotherapy okanye unyango olutsha lwe-hormonal (NHA) kwinqanaba le-mCRPC.
Idatha evela kwiqela lehlabathi lezigulana ezineenguqu ze-BRCA ibonise ukuba iLynparza kunye ne-Abiraterone ibonise ukuphucuka okubalulekileyo kwiklinikhi ekusindeni okungenazo iinguqu ze-radiographic (rPFS) xa kuthelekiswa ne-Abiraterone monotherapy. Uhlalutyo lwamaqela amancinci ezigulana ezineenguqu ze-BRCA kwiqela lehlabathi lubonise ukuba iLynparza edibene ne-Abiraterone inciphise umngcipheko wokuqhubela phambili kwesifo okanye ukufa nge-76% kunye nomngcipheko wokufa nge-70%. I-rPFS ephakathi kunye nokusinda okuqhelekileyo (OS) kwiqela leLynparza kunye ne-Abiraterone bekungekafikelelwa, ngelixa i-rPFS ephakathi kunye ne-OS ephakathi kwiqela le-Abiraterone monotherapy yayiziinyanga ezisi-8 kunye neenyanga ezingama-23, ngokulandelelana.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Ixesha lokuthumela: Agasti-07-2025